List of Excipients in Branded Drug OSMOLEX ER

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Vertical Pharmaceuticals LLC	OSMOLEX ER	amantadine	68025-075	CELLULOSE ACETATE
Vertical Pharmaceuticals LLC	OSMOLEX ER	amantadine	68025-075	CELLULOSE, MICROCRYSTALLINE
Vertical Pharmaceuticals LLC	OSMOLEX ER	amantadine	68025-075	COPOVIDONE K25-31
Vertical Pharmaceuticals LLC	OSMOLEX ER	amantadine	68025-075	D&C YELLOW NO. 10
Vertical Pharmaceuticals LLC	OSMOLEX ER	amantadine	68025-075	FD&C YELLOW NO. 6

Osmolex ER Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Osmolex ER is an extended-release amantadine hydrochloride tablet developed by Osmotica Pharmaceutical US LLC for Parkinson's disease and drug-induced extrapyramidal reactions. Its commercial value depends on controlled release, tablet manufacturability, renal-dose flexibility, and protection of the formulation platform. The principal excipient opportunity is not a simple reformulation of immediate-release amantadine. It is the development of a robust, lower-cost extended-release matrix or multiparticulate system that can match the pharmacokinetic profile while improving swallowability, food-effect control, dose flexibility, or manufacturing economics.

What is Osmolex ER and how does its formulation work?

Osmolex ER is a once-daily extended-release oral tablet containing amantadine hydrochloride. It is marketed in 129 mg, 193 mg, and 258 mg strengths, corresponding to 100 mg, 150 mg, and 200 mg of amantadine, respectively.[1]

The product is used for:

• Parkinson's disease.
• Drug-induced extrapyramidal reactions.

Amantadine has dopaminergic and NMDA-receptor antagonist activity. Conventional amantadine products generally require multiple daily doses, while Osmolex ER is designed to maintain exposure over a longer period with once-daily administration.

Core formulation objectives

The excipient system must achieve four technical objectives:

1. Slow amantadine release over the intended dosing interval.
2. Prevent dose dumping after tablet damage or abnormal gastrointestinal conditions.
3. Maintain tablet integrity during storage and transport.
4. Produce reproducible exposure across patients with variable renal function.

The marketed product uses a hydrophilic extended-release architecture. Public labeling identifies excipients including hypromellose, microcrystalline cellulose, lactose monohydrate, magnesium stearate, colloidal silicon dioxide, polyethylene glycol, polyvinyl alcohol, sodium lauryl sulfate, talc, titanium dioxide, and related coating materials.[1,2]

The precise quantitative composition and process parameters are not generally disclosed in the prescribing information. Those variables may remain commercially important even where the excipient names themselves are conventional.

What excipients are used in Osmolex ER?

The publicly disclosed excipient profile indicates a conventional but commercially useful combination of matrix-forming, tableting, lubrication, coating, and wetting agents.

Excipient or excipient class	Likely formulation function	Commercial relevance
Hypromellose	Hydrophilic release-controlling matrix	Central to release rate and dissolution profile
Microcrystalline cellulose	Diluent and compression aid	Supports tablet hardness and manufacturing yield
Lactose monohydrate	Diluent and bulking agent	Supports dose uniformity and tablet size
Magnesium stearate	Lubricant	Controls ejection force but can affect wetting and dissolution
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and content uniformity
Sodium lauryl sulfate	Wetting or surfactant function	Can improve hydration and dissolution of hydrophobic components
Polyethylene glycol	Coating or film-forming component	Supports coating performance and appearance
Polyvinyl alcohol	Film coating polymer	Improves mechanical protection and visual identification
Talc	Anti-tacking and coating aid	Supports coating-process efficiency
Titanium dioxide	Opacifier and colorant	Aesthetic and product-identification function

The highest-value excipient strategy is the interaction between hypromellose grade, particle size, viscosity, compression force, tablet porosity, lubricant level, and coating permeability. A competitor using the same excipient names can still produce a materially different product through a different release matrix and manufacturing process.

Why hypromellose is commercially important

Hypromellose is the likely primary rate-controlling polymer. Its viscosity grade, substitution pattern, particle morphology, concentration, and distribution through the tablet influence:

• Initial hydration.
• Gel-layer formation.
• Drug diffusion.
• Matrix erosion.
• Dose-strength proportionality.
• Release behavior after crushing or splitting.
• Sensitivity to agitation and pH.

A lower-cost generic strategy could use a different hypromellose grade, polyethylene oxide, hydroxypropyl cellulose, ethylcellulose, or a multiparticulate coating system. The substitute must demonstrate pharmaceutical equivalence and bioequivalence rather than chemical identity with the reference formulation.

What formulation opportunities exist for Osmolex ER competitors?

The strongest opportunities involve improvements that address clinical or manufacturing limitations rather than merely replacing one excipient.

1. Lower-cost hydrophilic matrix tablets

A direct generic product could use:

• Hypromellose with a different viscosity grade.
• A reduced-excipient formulation.
• A more efficient granulation process.
• Continuous manufacturing.
• Direct compression where powder properties permit.

Potential benefits include lower cost of goods, fewer supplier dependencies, and simpler scale-up. The main risk is that small changes in polymer hydration and tablet porosity can alter the full dissolution profile.

2. Multiparticulate extended-release capsules

A capsule containing coated amantadine beads or mini-tablets could offer:

• More consistent gastrointestinal distribution.
• Lower sensitivity to tablet geometry.
• Potentially improved dose proportionality.
• Easier manufacture of several strengths from a common bead population.
• Flexible release control through coating thickness.

This approach could have a stronger product profile but may face a more complex bioequivalence program. The dosage form would also create distinct intellectual-property exposure around pellet manufacture, coating composition, and dose assembly.

3. Abuse-deterrent or crush-resistant designs

Amantadine is not generally treated as a high-priority controlled substance, so abuse deterrence is unlikely to be the primary commercial driver. A crush-resistant design could still have value because extended-release products should not be crushed or chewed. A matrix that maintains controlled release after mechanical damage could support differentiation, but it would need a clinically meaningful labeling or safety rationale.

4. Smaller tablets and improved swallowability

Older patients with Parkinson's disease frequently take multiple medicines and may have dysphagia. A smaller tablet, multiparticulate product, or sprinkle-compatible dosage form could create a niche opportunity.

Potential designs include:

• Higher drug loading.
• A more efficient polymer matrix.
• Mini-tablets in a capsule.
• Oral granules.
• A film-coated product with improved surface properties.

A sprinkle product would require evidence that administration over soft food does not alter release, stability, or dose recovery.

5. Renal-function-oriented product architecture

Amantadine is substantially eliminated by the kidneys. The Osmolex ER label recommends lower starting doses and dose adjustments in patients with renal impairment.[1] A commercial opportunity exists for a presentation designed around renal dosing, such as:

• More granular strengths.
• A lower-dose extended-release tablet.
• A scored or divisible dosage form, if technically feasible.
• A multiparticulate package permitting dose customization.

This opportunity has clinical value but raises a formulation challenge: splitting or combining extended-release units must not produce excessive initial release.

When does Osmolex ER lose exclusivity?

Osmolex ER received FDA approval in 2018. FDA approval does not by itself establish a single generic-entry date because market entry depends on regulatory exclusivity, listed patents, Paragraph IV litigation, settlement terms, and the timing of ANDA approval.[1,3]

FDA exclusivity

The relevant regulatory framework includes:

• Five-year new chemical entity exclusivity if applicable.
• Three-year exclusivity for a product supported by new clinical investigations.
• Pediatric exclusivity, if granted.
• Patent-based delay under Hatch-Waxman litigation.

For an extended-release product containing an established active ingredient, the commercial protection is generally driven more by formulation patents and regulatory timing than by new chemical entity status.

Patent protection

The key patent risk is likely concentrated in:

• Extended-release amantadine compositions.
• Matrix architecture.
• Release profiles.
• Dosage regimens.
• Manufacturing processes.
• Specific strengths or pharmacokinetic parameters.

Public patent records associated with Osmotica's extended-release amantadine program include U.S. Patent No. 9,192,644, which covers aspects of extended-release amantadine formulations.[4] Patent term and Orange Book status must be evaluated against the live USPTO and FDA records because terminal disclaimers, patent-term adjustment, pediatric extensions, and listing changes can affect the effective date.

What is the Orange Book status of Osmolex ER?

The FDA Orange Book is the controlling commercial source for listed patents and exclusivity associated with approved drug products.[3] Osmolex ER should be evaluated by NDA 208944 and by each listed strength and dosage form.

The relevant Orange Book questions are:

Issue	Commercial effect
Whether formulation patents are listed	Determines Paragraph IV certification exposure
Whether method-of-use patents are listed	May permit label carve-outs or create litigation risk
Patent expiration date	Establishes the earliest ordinary patent-expiration pathway
Patent delisting or correction	Can alter ANDA certification strategy
Litigation within 45 days	Can trigger a 30-month approval stay
Settlement agreement terms	May establish a licensed or agreed generic-entry date

A generic applicant would typically assess Paragraph IV certification against listed formulation patents. A Paragraph IV notice can trigger litigation within 45 days. If the NDA holder sues within that period, FDA approval may be stayed for up to 30 months, subject to statutory exceptions and court action.[5]

What patent claims are most important for Osmolex ER?

Formulation patents

Formulation claims are likely to focus on:

• Amantadine embedded in a hydrophilic polymer matrix.
• Defined drug-to-polymer ratios.
• Release over a specified period.
• Specific dissolution behavior.
• Pharmacokinetic parameters.
• Tablet compositions containing selected excipient classes.

A generic formulation may avoid infringement by using a different polymer, a different dosage form, a different release mechanism, or a materially different dissolution profile. That strategy must be balanced against FDA bioequivalence requirements.

Method-of-use patents

Method-of-use claims could cover once-daily administration of extended-release amantadine for Parkinson's disease or drug-induced extrapyramidal reactions. A narrow indication patent may permit a section viii label carve-out if the generic product can be marketed without the patented use. A broad method claim can increase litigation risk.

Manufacturing patents

Manufacturing claims may cover:

• Wet granulation conditions.
• Polymer distribution.
• Compression force.
• Coating processes.
• Heat treatment.
• Multiparticulate coating thickness.
• Drug layering onto inert cores.

Manufacturing patents are harder to detect from the finished dosage form and can create freedom-to-operate risk even when a competitor avoids the principal composition claim.

How strong is the Osmolex ER patent estate?

The estate appears strongest where formulation composition and release performance are linked. A patent that claims a narrow excipient combination can be vulnerable to design-around. A patent that claims a broad release architecture supported by pharmacokinetic and dissolution data is more difficult to avoid.

Patent-estate factor	Assessment
Active ingredient	Weak barrier because amantadine is established and generic
Extended-release concept	Moderate barrier; multiple technical approaches exist
Specific matrix composition	Potentially strong if claims are broad and validated
Dissolution-profile claims	Stronger when tied to measurable release limits
Method-of-use claims	Variable; carve-outs may reduce exposure
Manufacturing claims	Potentially strong but difficult to identify and enforce
Device or packaging protection	Limited relevance unless a differentiated delivery system is used

The commercial defense therefore depends on the enforceability of formulation claims and the difficulty of reproducing the reference pharmacokinetic profile without using protected technical features.

Which companies are challenging or competing with Osmolex ER?

The competitive field includes three groups:

1. Generic amantadine immediate-release manufacturers.
2. Potential ANDA applicants for extended-release amantadine.
3. Branded or specialty products addressing Parkinson's symptoms through different mechanisms.

Immediate-release amantadine products are not direct therapeutic substitutes in every case because they require different dosing and produce different exposure profiles. Generic extended-release entrants would pose the greatest direct threat.

Potential competitors include large generic manufacturers with established modified-release capabilities, specialty generic companies, and contract development organizations that can transfer a hydrophilic matrix or multiparticulate platform into an ANDA program.

The most credible entrant profile would have:

• Existing modified-release tablet infrastructure.
• Experience with Paragraph IV litigation.
• Access to multiple hypromellose suppliers.
• In-house dissolution modeling.
• Capacity to conduct comparative pharmacokinetic studies.
• A commercial network covering neurology and retail pharmacy channels.

What revenue exposure does Osmolex ER create?

Osmolex ER's revenue exposure is concentrated in a narrow, chronic-use market. Parkinson's disease creates recurring demand, but the product competes with lower-cost immediate-release amantadine and other antiparkinsonian medicines.

The commercial variables are:

• Net price relative to generic immediate-release amantadine.
• Persistence with once-daily therapy.
• Prescriber preference for extended release.
• Reimbursement tier placement.
• Patient co-pay exposure.
• Availability of lower-cost generic extended-release products.
• The proportion of prescriptions attributable to drug-induced extrapyramidal reactions.

A single generic entrant can reduce price materially through pharmacy substitution. Multiple entrants generally accelerate erosion. The product may retain a premium if it demonstrates better adherence, smoother tolerability, lower pill burden, or improved renal-dose usability.

What licensing opportunities exist for Osmolex ER excipients and technology?

The most attractive licensing targets are platform technologies that improve release control without requiring a new active ingredient.

Excipient and platform licensing opportunities

• High-performance hypromellose or polyethylene oxide matrices.
• Co-processed excipients for direct compression.
• Multiparticulate coating systems.
• Taste-masking and swallowability technologies.
• Low-moisture granulation platforms.
• Continuous manufacturing systems.
• Predictive dissolution and in vitro-in vivo correlation tools.

An excipient supplier could license a proprietary polymer grade or co-processed blend to a generic manufacturer. The supplier's strongest protection would come from composition claims, grade-specific performance data, and process know-how rather than from the generic excipient name.

Commercial deal structures

Common structures include:

• Upfront payment plus milestone payments.
• Territory-limited rights.
• Supply agreement tied to minimum purchase volumes.
• Royalty based on net sales.
• Technology-transfer fees.
• Co-development with shared ANDA expenses.

For a product with moderate market size, a supply-plus-license model may be more attractive than a pure royalty model. The supplier can preserve value through long-term excipient sales even if composition patents are narrowed.

What generic launch scenarios exist for Osmolex ER?

Scenario	Likely commercial result
No approved extended-release generic before patent expiry	Branded product retains price and share
One approved generic after litigation	Rapid price reduction with limited initial competition
Multiple Paragraph IV entrants	Earlier risk and sharper net-price erosion
Authorized generic launch	Controlled price segmentation and channel defense
Non-infringing multiparticulate entrant	Potential entry despite matrix-patent protection
Lower-dose renal-focused entrant	Niche competition with limited direct substitution

The most disruptive scenario is an approved generic with a non-infringing release system and an FDA-compliant label that covers the principal marketed indications. A formulation patent may delay a conventional matrix-tablet competitor but may not block every extended-release design.

What regulatory barriers affect Osmolex ER competition?

FDA approval of a generic extended-release product is more demanding than approval of a simple immediate-release tablet. The applicant must address:

• Pharmaceutical equivalence.
• Comparable release characteristics.
• Fed and fasted pharmacokinetics.
• Dose proportionality where applicable.
• Strength-specific performance.
• Alcohol dose-dumping risk.
• Stability.
• Tablet robustness.
• Renal impairment considerations.
• Manufacturing-process reproducibility.

The FDA may accept a different excipient system if the product meets the applicable bioequivalence and quality standards. An excipient change becomes commercially valuable only when it improves manufacturing or product performance without creating a new clinical or regulatory burden.

Key Takeaways

• Osmolex ER is a once-daily extended-release amantadine hydrochloride tablet in 129 mg, 193 mg, and 258 mg strengths.
• Hypromellose is the likely principal release-controlling excipient.
• The most valuable formulation know-how lies in polymer grade, matrix geometry, porosity, compression, lubrication, and dissolution control.
• Commercial opportunities include lower-cost matrix tablets, multiparticulate capsules, smaller or sprinkle-compatible dosage forms, and renal-dose-oriented presentations.
• The principal patent risks involve extended-release compositions, dissolution profiles, methods of use, and manufacturing processes.
• Generic entry depends on Orange Book listings, Paragraph IV certifications, litigation, settlement terms, and FDA approval timing.
• A non-infringing multiparticulate or alternative-polymer product could bypass some matrix-patent barriers.
• Long-term commercial defense requires differentiation beyond excipient identity, including adherence, swallowability, dose flexibility, or demonstrated pharmacokinetic advantages.

FAQs

Can a generic manufacturer use the same excipients as Osmolex ER?

Yes. Excipients such as hypromellose, microcrystalline cellulose, lactose, and magnesium stearate are generally available to multiple manufacturers. The applicant must avoid infringing protected composition or process claims and must demonstrate acceptable quality and bioequivalence.

Is hypromellose alone enough to reproduce Osmolex ER?

No. Release depends on hypromellose grade and concentration, tablet porosity, particle size, compression force, drug loading, lubricant level, and coating. Matching the excipient list does not necessarily match the reference product.

Could an Osmolex ER competitor use polyethylene oxide instead of hypromellose?

Potentially. Polyethylene oxide can provide extended release, but the substitute formulation would require development, dissolution characterization, stability testing, and FDA-supported bioequivalence evidence. Patent claims covering broad hydrophilic matrices could still create freedom-to-operate risk.

Would an Osmolex ER sprinkle formulation have commercial value?

Yes, particularly for patients with dysphagia or difficulty swallowing tablets. The formulation would need to preserve extended release when administered with food or soft vehicle and would require a suitable regulatory pathway and labeling.

Are biosimilars relevant to Osmolex ER?

No. Osmolex ER is a small-molecule oral drug, not a biologic. Competition would proceed through generic-drug pathways, principally ANDAs, rather than biosimilar applications under the Public Health Service Act.

References

1. U.S. Food and Drug Administration. (2018). Osmolex ER (amantadine hydrochloride) extended-release tablets: Prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: Osmolex ER, amantadine hydrochloride extended-release tablets.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,192,644, extended-release amantadine formulations.
5. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2): Patent certifications and exclusivity under the Hatch-Waxman Act.